Arantxa Fornes-Urchueguia

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Incidence of Guillain-Barré Syndrome Following COVID-19 Vaccination and SARS-CoV-2 Infection: A Population-Based Cohort Study Using the Valencia Health System Integrated Database (Spain).

Incidence of Guillain-Barré Syndrome Following COVID-19 Vaccination and SARS-CoV-2 Infection: A Population-Based Cohort Study Using the Valencia Health System Integrated Database (Spain).

Journal: Pharmaceuticals (Basel, Switzerland)

Published: January 24, 2026

Validation of Guillain-Barré syndrome case identification in three heterogeneous VAC4EU real-world data sources in Spain using the Brighton Collaboration criteria.

Validation of Guillain-Barré syndrome case identification in three heterogeneous VAC4EU real-world data sources in Spain using the Brighton Collaboration criteria.

Journal: Vaccine

Published: July 31, 2025

Hospitalisation trends of respiratory syncytial virus (RSV) infection in adults, six European countries, before and during COVID-19, 2016 to 2023.

Hospitalisation trends of respiratory syncytial virus (RSV) infection in adults, six European countries, before and during COVID-19, 2016 to 2023.

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Published: June 27, 2025

Clinical Course, Outcomes, and Risk Factors of Myocarditis and Pericarditis Following Administration of mRNA-1273 Vaccination: A Protocol for a Federated Real-World Evidence Vaccine Safety Study Using Data from Five European Data Sources.

Clinical Course, Outcomes, and Risk Factors of Myocarditis and Pericarditis Following Administration of mRNA-1273 Vaccination: A Protocol for a Federated Real-World Evidence Vaccine Safety Study Using Data from Five European Data Sources.

Journal: Vaccines

Published: May 30, 2025

Risk of thrombosis with thrombocytopaenia syndrome (TTS) after vaccination with AZD1222: a European VAC4EU post-authorisation safety study.

Risk of thrombosis with thrombocytopaenia syndrome (TTS) after vaccination with AZD1222: a European VAC4EU post-authorisation safety study.

Journal: Vaccine

Published: May 30, 2025

Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.

Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.

Journal: Vaccine

Published: April 30, 2025

Estimating the respiratory syncytial virus-associated hospitalisation burden in older adults in European countries: a systematic analysis.

Estimating the respiratory syncytial virus-associated hospitalisation burden in older adults in European countries: a systematic analysis.

Journal: BMC medicine

Published: February 14, 2025

Respiratory syncytial virus hospitalisation burden in children below 18 years in six European countries (2016-2023) pre- and post-COVID-19 pandemic.

Respiratory syncytial virus hospitalisation burden in children below 18 years in six European countries (2016-2023) pre- and post-COVID-19 pandemic.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: January 13, 2025

Corrigendum to "A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases" [Vaccine 42 (12) (2024) 3039-3048].

Corrigendum to "A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases" [Vaccine 42 (12) (2024) 3039-3048].

Journal: Vaccine

Published: October 13, 2024

Estimation of respiratory syncytial virus-associated hospital admissions in five European countries: a modelling study.

Estimation of respiratory syncytial virus-associated hospital admissions in five European countries: a modelling study.

Journal: The Lancet regional health. Europe

Published: August 14, 2024

Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: a multi-country analysis.

Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: a multi-country analysis.

Journal: BMC medicine

Published: August 01, 2024

Ten-Year Surveillance of Respiratory Syncytial Virus Hospitalizations in Adults: Incidence Rates and Case Definition Implications.

Ten-Year Surveillance of Respiratory Syncytial Virus Hospitalizations in Adults: Incidence Rates and Case Definition Implications.

Journal: The Journal of infectious diseases

Published: July 10, 2024

Showing 1-12 of 14

Last Updated: 09/26/2026